Inhibikase Therapeutics Competitors

ImmunoPrecise Antibodies (NASDAQ:IPA) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Earnings and Valuation

This table compares ImmunoPrecise Antibodies and Inhibikase Therapeutics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ImmunoPrecise Antibodies and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for ImmunoPrecise Antibodies and Inhibikase Therapeutics, as reported by MarketBeat.com.

Longboard Pharmaceuticals (NASDAQ:LBPH) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Longboard Pharmaceuticals and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent ratings for Longboard Pharmaceuticals and Inhibikase Therapeutics, as provided by MarketBeat.com.

Longboard Pharmaceuticals presently has a consensus target price of $32.75, suggesting a potential upside of 169.55%. Given Longboard Pharmaceuticals' higher possible upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Inhibikase Therapeutics.

Profitability

This table compares Longboard Pharmaceuticals and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Summary

Longboard Pharmaceuticals beats Inhibikase Therapeutics on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Annovis Bio and Inhibikase Therapeutics, as reported by MarketBeat.

Profitability

This table compares Annovis Bio and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Annovis Bio and Inhibikase Therapeutics' gross revenue, earnings per share and valuation.

Inhibikase Therapeutics (NYSE:IKT) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Inhibikase Therapeutics and Gain Therapeutics, as provided by MarketBeat.

Gain Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 113.93%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Inhibikase Therapeutics.

Profitability

This table compares Inhibikase Therapeutics and Gain Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Inhibikase Therapeutics and Gain Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Gain Therapeutics beats Inhibikase Therapeutics on 2 of the 2 factors compared between the two stocks.

Inhibikase Therapeutics (NYSE:IKT) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Valuation & Earnings

This table compares Inhibikase Therapeutics and Vincerx Pharma's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Inhibikase Therapeutics and Vincerx Pharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Inhibikase Therapeutics and Vincerx Pharma, as provided by MarketBeat.

Given Vincerx Pharma's higher possible upside, analysts plainly believe Vincerx Pharma is more favorable than Inhibikase Therapeutics.

Summary

Vincerx Pharma beats Inhibikase Therapeutics on 2 of the 2 factors compared between the two stocks.

Evaxion Biotech A/S (NASDAQ:EVAX) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Evaxion Biotech A/S and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Evaxion Biotech A/S and Inhibikase Therapeutics, as provided by MarketBeat.

Evaxion Biotech A/S currently has a consensus target price of $18.00, suggesting a potential upside of 145.57%. Given Evaxion Biotech A/S's higher probable upside, equities analysts clearly believe Evaxion Biotech A/S is more favorable than Inhibikase Therapeutics.

Summary

Evaxion Biotech A/S beats Inhibikase Therapeutics on 2 of the 2 factors compared between the two stocks.